3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Tumor-Agnostic
3
CNS
3
Head & Neck
2
Gastrointestinal
2
Dermatologic
2
Breast
2
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
lutetium Lu 177 dotatate
18
Everolimus
13
Temozolomide
12
Nivolumab
10
pembrolizumab
9
cabozantinib
8
Capecitabine
8
Sunitinib
7
lenvatinib
5
Magnetic Resonance Spectroscopy
5
Etoposide
5
lanreotide
4
gallium Ga 68 dotatate
4
Specimen Handling
4
Ipilimumab
4
Cisplatin
4
Carboplatin
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
telotristat ethyl
3
surufatinib
3
pazopanib
3
avelumab
3
Octreotide
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Bevacizumab
3
sintilimab
2
fosbretabulin
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
entrectinib
×
NET
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA